These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Velasco-Torrijos T Manuscript Alternative scaffolds.pdf (1.28 MB)

Scaffold Diversity for Enhanced Activity of Glycosylated Inhibitors of Fungal Adhesion

submitted on 13.05.2020, 13:35 and posted on 14.05.2020, 11:21 by Tobias Krämer, kevin kavanagh, Trinidad Velasco-Torrijos, Harlei Martin, Tara Somers, Fred Pfeiffer, Ryan Robson, Mathew Dwyer
Candida albicans is one of the most prevalent fungal pathogens involved in
hospital acquired infections. It uses adhesins to bind to glycans at the cell surface of epithelial
cells and thus initiate infection. These interactions can be blocked by synthetic carbohydrates
(such as compound 1) that mimics the structure of cell surface glycans. Herein we report the
synthesis of a new series of divalent galactosides featuring aromatic (benzene, squaramides)
and aliphatic (norbornenes) central scaffolds, with the latter being the first examples of their
kind as small molecule anti-adhesion glycoconjugates. The evaluation of these compounds as
inhibitors of adhesion of C. albicans o exfoliated buccal epithelial cells (BECs) revealed that
galactosides 1 and 6, built on an aromatic core, were the most efficient inhibitors of adhesion,
displacing up to 36% and 48%, respectively, of yeast cells already attached to the BECs at
0.138 μM. Conformational analysis of compound 1 identified the preference for a folded
presentation in the lowest energy conformers. Remarkably, cis-endo-norbornene 21 performed
comparably to the benzene-core derivatives, highlighting the potential of norbornenes as a new
class of aliphatic scaffolds for the synthesis of anti-adhesion compounds.


Maynooth University Hume Scholarship


Email Address of Submitting Author


Maynooth University



ORCID For Submitting Author

Declaration of Conflict of Interest

no conflict of interest

Version Notes

manuscript version 1